Study details
Enrolling now
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Takeda
NCT IDNCT06100289ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
70
Study length
about 2.4 years
Ages
2–17
Locations
11 sites in CA, IL, MI +5
What this study is about
This trial is testing how the body processes vedolizumab, a drug given under the skin (SC), in children and teenagers with ulcerative colitis or Crohn's disease. Participants will receive vedolizumab for up to 34 weeks.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Vedolizumab IV
- 2.Take Vedolizumab SC
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
vedolizumab
Drug routes
injection, intravenous, infusion
Body systems
Gastroenterology